Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Naltrexone may fight breast
cancer by blocking the use of estrogen by the tumor cells. Naltrexone may also stop the
growth of breast cancer by impairing blood flow to the tumor.
PURPOSE: This phase II trial is studying how well naltrexone works in treating women with
metastatic breast cancer that is no longer responsive to previous hormone therapy.